Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11708435.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As more individuals receive outer surface protein A (OspA) vaccination, adverse effects not detected during phase III clinical trials may become apparent. Although arthritis has been described following other human vaccines, we found no reports of human cases after Lyme disease vaccination. We describe 4 males (2 children, 2 adults) who developed arthritis following recombinant OspA vaccination. The potential arthritogenic effect of OspA suggested by in vitro and animal studies finds a clinical correlate in these 4 cases.
Medical subject headings
- Antigens, Surface
- Arthritis, Reactive
- Bacterial Outer Membrane Proteins
- Lipoproteins
- Lyme Disease
- Lyme Disease Vaccines